A study conducted by Liu et al. in patients undergoing ICI therapy showed that the use of PCSK9 inhibitors can also enhance the effectiveness of immunotherapy by up-regulating the expression of MHC-I on tumor cells [86]. Here, PCSK9 is linked to neoplasm.